Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance

Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients

(2017) Jesús Troya et al.   Open Forum Infectious Diseases

Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children

(2016) Nienke J. Vet et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation

(2015) Nikolas Itaru Wada et al.   AIDS

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

(2015) DE Coutant et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis

(2015) Rui Ding et al.   CLINICAL RHEUMATOLOGY

Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients

(2015) Ana Leonor Pardo Campos Godoy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

(2014) R Donald Harvey et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate

(2013) P. N. Morcos et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis

(2013) Xiaoping Zhang et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

IL-1βand IL-6 Upregulation in Children with H1N1 Influenza Virus Infection

(2013) Antonio Chiaretti et al.   MEDIATORS OF INFLAMMATION

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

(2012) Sravanthi Cheeti et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

The Clinical Relevance of Plasma Protein Binding Changes

(2012) Jason A. Roberts et al.   CLINICAL PHARMACOKINETICS

Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis

(2012) Sergey P. Oranskiy et al.   CROATIAN MEDICAL JOURNAL

Serum level of interleukin-6 in Chinese patients with multiple sclerosis

(2012) Ying-Chun Chen et al.   JOURNAL OF NEUROIMMUNOLOGY

Levels of Amyloid Beta-42, Interleukin-6 and Tumor Necrosis Factor-Alpha in Alzheimer’s Disease and Vascular Dementia

(2012) Sema Uslu et al.   NEUROCHEMICAL RESEARCH

Drug−disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity

(2011) Forough Sanaee et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture

(2011) L. J. Dickmann et al.   DRUG METABOLISM AND DISPOSITION

Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers

(2011) Gopal Krishna et al.   Expert Opinion on Drug Metabolism & Toxicology

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

(2011) Maria Cristina Villarroel et al.   INVESTIGATIONAL NEW DRUGS

Intensive Cytokine induction in Pandemic H1N1 Influenza Virus Infection Accompanied by Robust Production of IL-10 and IL-6

(2011) Xuelian Yu et al.   PLoS One

Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer

(2011) Wei Chua et al.   SUPPORTIVE CARE IN CANCER

Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response

(2011) Alexander M Cressman et al.   Expert Review of Clinical Pharmacology

Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis

(2010) G. HORNEFF et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CYP-Mediated Therapeutic Protein-Drug Interactions

(2010) Jang-Ik Lee et al.   CLINICAL PHARMACOKINETICS

Variability in drug metabolizing enzyme activity in HIV-infected patients

(2010) Amanda E. Jones et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Synergistic antifibrotic effect of verapamil and interferon-γ in rats: partially based on enhanced verapamil oral bioavailability

(2010) Dan Xu et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus

(2010) J. YIP et al.   JOURNAL OF RHEUMATOLOGY

The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients

(2010) Soo-Jin Chung et al.   YONSEI MEDICAL JOURNAL

Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

(2009) A. Barrail-Tran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection

(2009) Xiang-Rui Wang et al.   CANCER SCIENCE

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS

High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia

(2009) Alessandro Antonelli et al.   CLINICAL RHEUMATOLOGY

Different Effects of Ketoconazole on the Stereoselective First-Pass Metabolism of R/S-Verapamil in the Intestine and the Liver: Important for the Mechanistic Understanding of First-Pass Drug-Drug Interactions

(2009) H. A. Thorn et al.   DRUG METABOLISM AND DISPOSITION

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

(2008) Rosie Z Yu et al.   CLINICAL PHARMACOKINETICS

Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

(2008) E. T. Morgan et al.   DRUG METABOLISM AND DISPOSITION

Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients

(2008) K. Nakai et al.   DRUG METABOLISM AND DISPOSITION

Effects of Infliximab and Parenteral Nutrition on Albumin and Fibrinogen Synthesis Rates in Pediatric Crohn Disease

(2008) Steven J Steiner et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone

(2008) Tuomas Korhonen et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis

(2003) Patrick R. Mayo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY